Collegium Pharmaceutical (COLL) – Analysts’ Weekly Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Collegium Pharmaceutical (NASDAQ: COLL) in the last few weeks:

• 11/7/2026 – Collegium Pharmaceutical was upgraded by Wall Street Zen from “hold” to “buy”.
• 11/6/2026 – Collegium Pharmaceutical had its “buy” rating reaffirmed by Jefferies Financial Group. They now have a $35.00 price target on the stock.
• 11/6/2026 – Collegium Pharmaceutical had its price target lowered by Piper Sandler from $43.00 to $28.00. They now have a “neutral” rating on the stock.
• 11/5/2026 – Collegium Pharmaceutical had its price target lowered by Needham & Company LLC from $46.00 to $44.00. They now have a “buy” rating on the stock.
• 10/15/2026 – Collegium Pharmaceutical was upgraded by Zacks Research from “strong sell” to “strong-buy”.
• 10/6/2026 – Collegium Pharmaceutical was downgraded by Zacks Research from “hold” to “strong sell”.
• 9/23/2026 – Collegium Pharmaceutical is now covered by Oppenheimer. They set an “outperform” rating and a $50.00 price target on the stock.

Collegium Pharmaceutical Stock Performance

NASDAQ COLL traded down $0.47 on Tuesday, reaching $24.23. The stock had a trading volume of 162,398 shares, compared to its average volume of 582,399. The company has a debt-to-equity ratio of 3.32, a current ratio of 1.03 and a quick ratio of 0.84. The firm has a fifty day moving average of $22.98 and a two-hundred day moving average of $32.68. Collegium Pharmaceutical, Inc. has a 1-year low of $21.43 and a 1-year high of $50.79. The company has a market cap of $789.09 million, a P/E ratio of 24.23, a price-to-earnings-growth ratio of 0.74 and a beta of 0.75.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Thursday, November 5th. The specialty pharmaceutical company reported $1.96 earnings per share for the quarter, topping analysts’ consensus estimates of $1.86 by $0.10. The company had revenue of $216.34 million during the quarter, compared to the consensus estimate of $216.03 million. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%. The company’s revenue was up 67.4% on a year-over-year basis. During the same quarter last year, the firm earned $2.25 earnings per share. On average, equities research analysts anticipate that Collegium Pharmaceutical, Inc. will post 6.42 EPS for the current year.

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on developing and commercializing medicines for pain management and central nervous system disorders. The company primarily serves the U.S. market and emphasizes products designed to address significant patient and healthcare-provider needs. Its pain portfolio includes Xtampza ER, an extended-release oxycodone formulation designed with abuse-deterrent properties, as well as Nucynta and Nucynta ER, which contain tapentadol and are used to treat acute and chronic pain.